BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

Zacks Research raised their Q3 2025 earnings estimates for BioMarin Pharmaceutical in a report released on Monday, February ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Wednesday reported fourth-quarter profit of $124.9 million. The San Rafael, California-based company said it ...